Benzinga | Nov 18, 2021 07:06AM EST

AbbVie Announces First Provincial Reimbursement For VENCLEXTA With Obinutuzumab For Patients With Previously Untreated Chronic Lymphocytic Leukemia In Quebec

* Following the signing of an agreement between AbbVie and the pan-Canadian Pharmaceutical Alliance (pCPA), Quebec is the first province to reimburse the combination treatment.

* VENCLEXTA(r) (venetoclax) plus obinutuzumab is the first chemotherapy-free, fixed-duration combination regimen approved by Health Canada for patients with previously untreated chronic lymphocytic leukemia (CLL).